Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
4(44.4%)
Early Phase 1
3(33.3%)
Phase 2
2(22.2%)
9Total
Phase 1(4)
Early Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07210632Early Phase 1Recruiting

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Role: lead

NCT07493447Early Phase 1Not Yet Recruiting

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Role: lead

NCT06922825Early Phase 1Withdrawn

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

Role: lead

NCT05747625Phase 1Recruiting

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Role: lead

NCT03405142Phase 2Completed

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Role: lead

NCT02415881Phase 1Completed

Panitumumab IRDye800 Optical Imaging Study

Role: lead

NCT02855086Phase 1Terminated

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

Role: lead

NCT02736578Phase 2Terminated

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Role: lead

NCT01987375Phase 1Terminated

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Role: lead

All 9 trials loaded